← All trials
NCT05517174
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2022
- Primary completion
- May 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Aug 26, 2022
- Last posted
- Sep 26, 2022
- Enrollment
- 208000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CopenhagenLead sponsor
- SanofiCollaborator
- Statens Serum InstitutCollaborator
- University of CopenhagenSponsor investigator
- University of CopenhagenStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.